Litcius/Paper detail

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial

Satoshi Ebata, Ayumi Yoshizaki, Koji Oba, Kosuke Kashiwabara, Keiko Ueda, Yukari Uemura, Takeyuki Watadani, Takemichi Fukasawa, Shunsuke Miura, Asako Yoshizaki‐Ogawa, Naoko Okiyama, Masanari Kodera, Minoru Hasegawa, Shinichi Sato

2022The Lancet Rheumatology75 citationsDOI

Topics & Concepts

MedicinePlaceboRituximabClinical endpointRheumatismInternal medicineClinical trialRheumatologyOpen labelDouble blindPhysical therapySurgeryLymphomaPathologyAlternative medicineSystemic Sclerosis and Related DiseasesMultiple Sclerosis Research StudiesDupuytren's Contracture and Treatments
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial | Litcius